Mayo Clinic Lymphoma eTumor Board | Splenic marginal zone lymphoma with massive splenomegaly


This case study discusses the presentation and management of an asymptomatic, previously-untreated patient with splenic marginal zone lymphoma accompanied by massive splenomegaly and minimal lymphadenopathy. The possibility of splenectomy and/or treatment with chemoimmunotherapy (bendamustine + rituximab) or single-agent rituximab is discussed between the experts.

This patient case study has been graciously provided to the Lymphoma Hub by the Mayo Clinic Lymphoma eTumor Board (August 21, 2019). The treatment options discussed in this video represent the opinion of the Mayo Clinic experts based on North-America guidelines, drug approvals in the US or clinical trials.